A phase 3 trial evaluating a nebulized clofazimine inhalation suspension (MNKD-101) for the treatment of refractory nontuberculous mycobacterial (NTM) lung disease has been discontinued. The ...

Add Yahoo as a preferred source to see more of our stories on Google. NTM are opportunistic pathogens responsible for causing infections in patients with pre-existing health conditions or compromised ...

BRIDGEWATER, N.J., July 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

For most Americans, the letters "NTM" don’t mean anything. But for tens of thousands of people across the country, they represent something serious: a chronic lung disease that’s often overlooked, ...

MIAMI, Aug. 4, 2025 /PRNewswire/ -- As the world prepares to observe World NTM Day on August 4, 2025, NTM Info & Research (NTMir) is calling on patients, physicians, caregivers, and policy leaders to ...

Please provide your email address to receive an email when new articles are posted on . The ICoN-1 trial has been discontinued, and futility was the reason for this decision. The company is still ...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD), a company focused on the development and commercialization of innovative inhaled ...

Miami (July 31, 2025) – The Bronchiectasis and NTM Association joins other global patient advocacy organizations, professional societies, and lung health experts for the third annual World NTM ...

BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving ...

About MAC Lung Disease Mycobacterium avium complex (MAC) lung disease is a rare and serious disorder that can significantly increase morbidity and mortality. Patients with MAC lung disease can ...

Patients with comorbid respiratory disease were significantly more likely to develop nontuberculosis mycobacterial pulmonary disease (NTM-PD), data from a systematic review of 99 studies indicate. NTM ...